Who We Are
Human Predictions is a pharmacometrics and clinical pharmacology consultancy focused on turning complex, disconnected data into actionable knowledge. Our specialty is integrating diverse data sources and analytical approaches to increase confidence and precision in drug development decisions.
We have contributed to the success of more than 100 biotechnology and pharmaceutical companies by supporting clinical development strategy, regulatory interactions and filings, in-licensing and out-licensing decisions, clinical and nonclinical study design, and comparisons of standard of care with novel therapeutics. Our experience spans a broad range of therapeutic areas and treatment modalities, including small molecules; large molecules such as monoclonal and polyclonal antibodies, antibody–drug conjugates, bispecific and trispecific therapies, proteins, and peptides; as well as RNA-based therapeutics, cell-based therapies, and gene therapies. We partner closely with our clients to focus drug development through efficient experimentation, innovative analyses, and the transformation of complex datasets into clear, decision-ready insights.
What We Do for You
Our clinical, pharmacometric, and statistical analyses deliver the right answer at the right time, with the appropriate level of rigor for your stage of development. Having worked within clinical development teams, we understand the realities of tight timelines, evolving strategies, and the need to communicate clearly with a broad range of stakeholders.We take a collaborative, tailored approach—working with you to understand your specific questions and development context, and designing solutions that align with your program’s goals. Drawing on experience defining clinical strategy and running trials across multiple therapeutic areas, we balance clinical feasibility, regulatory expectations, and statistical rigor at every stage of development.
Our most effective collaborations often begin from a blank slate—“How can we work together?”—an approach that has supported regulatory acceleration, program de-risking, and, in several cases, multi-billion-dollar value creation and dramatic reductions in development timelines.
How We Find Solutions
- Model-based meta-analyses (MBMA)
- Translational research from nonclinical studies through disease progression and early clinical development (e.g., Phase 0)
- Model-based study powering
- Population pharmacokinetics and pharmacodynamics (PopPK and PopPK/PD)
- Clinical trial simulation (CTS)
- Big-data analyses across diseases, drugs, and therapeutic areas
- Noncompartmental analysis (NCA)
- Data visualization, including interactive graphics (e.g., Shiny)
- Novel, fit-for-purpose analytical methodologies tailored to your specific needs
